Title:
NHRI technology, “DBPR211: a peripheral CB1 receptor antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing.
Description:
Cannabinoid receptor 1 (CB1) is expressed in several peripheral tissues related to metabolic control and its dysregulation contributes to metabolic disorders. DBPR211 is a highly selective antagonist of peripheral CB1 receptors. It exhibits beneficial effects in treating insulin resistance, obesity and non-alcoholic fatty liver disease. This unique mechanism may potentially render DBPR211 as a highly competitive first-in-class drug candidate for the treatment of type 2 diabetes, obesity and non-alcoholic fatty liver disease.
Potential collaboration partner qualifications:
- be incorporated and approved by law and does not have any record of misconduct or conviction for any offense
- better to have related experience and skills for developing The Technology
- better to have experience of international collaboration and clinical trial
- be willing to provide long-term investment
Registration:
Please contact to Mr. Hua-Hsuan Liang (Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan, R.O.C., Tel: +88637-246166#33206, E-mail: huahsuan@nhri.org.tw).
Other:
If The Technology has been exclusively licensed, this announcement will automatically invalid. For detailed status of The Technology, please contact to the case officer.
Attachments:
I: Announcement